HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chia-Chi Lin Selected Research

Ramucirumab

1/2021Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
12/2020Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
1/2020Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chia-Chi Lin Research Topics

Disease

76Neoplasms (Cancer)
01/2024 - 09/2004
41Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2024 - 05/2008
15Esophageal Squamous Cell Carcinoma
01/2023 - 07/2007
14Disease Progression
05/2023 - 06/2016
13Carcinoma (Carcinomatosis)
01/2020 - 09/2004
12Neoplasm Metastasis (Metastasis)
06/2022 - 03/2007
10Thyroid Neoplasms (Thyroid Cancer)
12/2023 - 01/2017
9Esophageal Neoplasms (Esophageal Cancer)
01/2023 - 11/2002
7Prostatic Neoplasms (Prostate Cancer)
10/2023 - 03/2006
7Hepatocellular Carcinoma (Hepatoma)
06/2022 - 02/2007
7Adenocarcinoma
01/2020 - 11/2015
6Lung Neoplasms (Lung Cancer)
01/2020 - 09/2014
5Fatigue
12/2022 - 10/2016
4Renal Cell Carcinoma (Grawitz Tumor)
01/2024 - 03/2013
4Hypertension (High Blood Pressure)
12/2022 - 05/2009
4Squamous Cell Carcinoma of Head and Neck
02/2022 - 11/2016
4Diarrhea
01/2021 - 03/2013
3Melanoma (Melanoma, Malignant)
01/2024 - 01/2020
3Colorectal Neoplasms (Colorectal Cancer)
11/2023 - 02/2020
3Inflammation (Inflammations)
10/2023 - 01/2009
3Thymoma (Thymic Carcinoma)
01/2022 - 01/2018
3Nausea
01/2022 - 03/2013
3Breast Neoplasms (Breast Cancer)
10/2021 - 01/2007
3Hemorrhage
01/2021 - 04/2018
3Urinary Bladder Neoplasms (Bladder Cancer)
11/2019 - 10/2009
3Infections
12/2017 - 06/2002
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2017 - 11/2015
2medullary Thyroid cancer
11/2023 - 01/2021
2Pneumonia (Pneumonitis)
10/2023 - 01/2020
2Anaplastic Thyroid Carcinoma
06/2022 - 10/2020
2Febrile Neutropenia
12/2020 - 08/2011
2Adenocarcinoma of Lung
01/2020 - 01/2020
2Lymphoma (Lymphomas)
01/2019 - 08/2015
2Thrombocytopenia (Thrombopenia)
01/2019 - 08/2011
2Exanthema (Rash)
11/2017 - 05/2009
2Stomach Neoplasms (Stomach Cancer)
09/2017 - 06/2016

Drug/Important Bio-Agent (IBA)

24ErbB Receptors (EGF Receptor)IBA
01/2020 - 03/2006
22Cisplatin (Platino)FDA LinkGeneric
07/2022 - 11/2002
20Tyrosine Kinase InhibitorsIBA
01/2020 - 01/2009
12Paclitaxel (Taxol)FDA LinkGeneric
07/2022 - 03/2006
12Gefitinib (Iressa)FDA Link
01/2017 - 03/2006
11Fluorouracil (Carac)FDA LinkGeneric
06/2019 - 11/2002
8B7-H1 AntigenIBA
11/2023 - 11/2016
8pembrolizumabIBA
01/2023 - 06/2016
8Leucovorin (Folinic Acid)FDA Link
06/2019 - 11/2002
8Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2017 - 05/2009
7Biomarkers (Surrogate Marker)IBA
01/2023 - 09/2010
6spartalizumabIBA
01/2024 - 01/2020
6cabozantinibIBA
12/2023 - 02/2013
6lorlatinibIBA
05/2023 - 12/2018
6Anaplastic Lymphoma KinaseIBA
01/2022 - 09/2015
5Immune Checkpoint InhibitorsIBA
01/2023 - 10/2019
5PlatinumIBA
01/2022 - 10/2011
5AfatinibIBA
01/2017 - 03/2016
4Sorafenib (BAY 43-9006)FDA Link
12/2023 - 08/2011
4Monoclonal AntibodiesIBA
11/2023 - 09/2017
4CrizotinibIBA
05/2023 - 12/2018
4LigandsIBA
02/2022 - 11/2019
4DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2013
4osimertinibIBA
01/2021 - 01/2017
4GemcitabineFDA Link
08/2018 - 04/2007
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2024 - 06/2014
3lenvatinibIBA
12/2023 - 01/2022
3IodineIBA
11/2023 - 01/2017
3Alkaline PhosphataseIBA
01/2022 - 03/2007
3Phosphotransferases (Kinase)IBA
10/2021 - 04/2014
3Proteins (Proteins, Gene)FDA Link
05/2021 - 11/2019
3Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2021 - 06/2014
3RamucirumabIBA
01/2021 - 01/2020
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2021 - 11/2017
3Arsenic Trioxide (Trisenox)FDA Link
11/2008 - 09/2004
3Methotrexate (Mexate)FDA LinkGeneric
01/2007 - 11/2002
2pralsetinibIBA
11/2023 - 01/2021
2vandetanib (ZD6474)IBA
11/2023 - 01/2021
2xentuzumabIBA
10/2023 - 01/2020
2durvalumabIBA
01/2023 - 01/2020
2sapanisertibIBA
05/2022 - 01/2022
2siremadlinIBA
03/2022 - 01/2022
2AntibodiesIBA
01/2022 - 05/2021
2LY3300054IBA
12/2021 - 01/2021
2trastuzumab deruxtecanIBA
11/2021 - 10/2021
2entrectinibIBA
10/2021 - 01/2020
2Creatine Kinase (Creatine Phosphokinase)IBA
01/2021 - 10/2016
2pexidartinibIBA
01/2021 - 01/2020
2Alanine Transaminase (SGPT)IBA
01/2020 - 11/2017
2Epidermal Growth Factor (EGF)IBA
11/2019 - 09/2010
2NivolumabIBA
01/2018 - 01/2018
2Dihydrotachysterol (AT 10)IBA
11/2016 - 05/2009

Therapy/Procedure

38Therapeutics
01/2024 - 04/2007
26Drug Therapy (Chemotherapy)
01/2022 - 11/2002
7Chemoradiotherapy
08/2019 - 10/2009
6Esophagectomy
08/2019 - 06/2009
5Castration
10/2023 - 02/2013
5Neoadjuvant Therapy
07/2022 - 06/2009
4Immunotherapy
10/2023 - 01/2018
4Induction Chemotherapy
11/2019 - 10/2009
4Radiotherapy
08/2018 - 06/2009
3Combination Drug Therapy (Combination Chemotherapy)
01/2014 - 11/2002
2Duration of Therapy
02/2022 - 11/2017
2TP protocol
06/2019 - 01/2007